Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Novavax, Inc. and Takeda Pharmaceutical Company Limited today announced the initiation of a Phase 1/2 clinical trial in Japan of NVX-CoV2373, Novavax's…
Japan will buy 150 million doses of Novavax's COVID-19 vaccine candidate from Takeda Pharmaceutical, the two companies said on Tuesday, expanding the country's…
On August 7, 2020, we entered into a Collaboration and License Agreement with Takeda for the development, manufacturing and commercialization of NVX-CoV2373 in…
Source summaries from our enrichment pipeline; follow links for originals.
All 16 sources with sentiment breakdown →
In August 2021 Takeda and Novavax agreed for Takeda to manufacture in Japan and supply the Government of Japan with 150 million doses of Novavax's recombinant protein nanoparticle COVID-19 vaccine NVX-CoV2373 (TAK-019), under a technology-transfer and license arrangement (deal value estimated ~$350M). The agreement became operational: on April 19, 2022 Japan's MHLW granted Takeda manufacturing and marketing approval for Nuvaxovid for primary and booster immunization in adults 18+, and Takeda began distributing government-purchased doses. Demand proved far below plan — on February 13, 2023 Takeda disclosed that the Japanese government had canceled the remaining 141.76 million of the 150 million doses, citing low uptake (Takeda said the cancellation would not materially affect its forecast). On December 25, 2023 Japan ended distribution of Nuvaxovid as the supplied product reached expiry, with roughly 7.14 million doses discarded. Net: the deal was executed and the vaccine reached the Japanese market, but only a small fraction of the contracted volume was ultimately used.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd. / Novavax Inc. (this deal) | 2021 | $350M | — |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
| Takeda Pharmaceutical Company Ltd. / Nycomed | 2011 | $13.7B | 72 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
| Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. | 2018 | $1.2B | 64 |
← Browse all deals · How we score deals
More: 2021 deals · Takeda Pharmaceutical Company Ltd. deals · Vaccines deals